Portal de Periódicos da CAPES

Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450( CYP ) Inhibitors and/or with CYP Inhibitors plus CYP Inducers

2015; Wiley; Volume: 118; Issue: 6 Linguagem: Inglês

10.1111/bcpt.12530

1742-7843

Pier Giorgio Cojutti, Anna Candoni, Fabio Forghieri, Miriam Isola, Maria Elena Zannier, Sara Bigliardi, Mario Luppi, Renato Fanin, Federico Pea,

Pneumocystis jirovecii pneumonia detection and treatment

Voriconazole plasma exposure greatly varies among haematological patients. The purpose of this study was to identify the magnitude of influence of comedications with CYP inhibitors and/or with CYP inhibitors plus CYP inducers on voriconazole trough level (Cmin ). Voriconazole Cmin was retrospectively assessed among haematological patients who underwent therapeutic drug monitoring (TDM). Univariate and multivariate linear mixed-effect regression analyses were performed to identify the independent predictors of normalized Cmin . Of the 83 included patients, 35 had comedications with CYP inhibitors (omeprazole or pantoprazole) and 21 with CYP inhibitors (omeprazole or pantoprazole) plus CYP inducers (methylprednisolone, dexamethasone, phenobarbital, rifampin or carbamazepine). Median Cmin value (n = 199) was 2.4 mg/L with a wide range of distribution ( 5.5 mg/L (OR: 23.22, 95% CI: 3.01-179.09, p = 0.003). No significant association emerged when CYP inhibitors were coadministered with CYP inducers (OR: 3.53, 95% CI: 0.36-34.95, p = 0.280). The amount of expected Cmin increase was significantly influenced by both the type and the dose of the administered proton pump inhibitor. The study highlights that the benefit from TDM of voriconazole may be maximal in those patients who are cotreated with CYP inhibitors and/or with CYP inhibitors plus CYP inducers, especially when receiving proton pump inhibitors (PPIs) at very high dosages intravenously.